EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Primary retroperitoneal lymph node dissection for metastatic non‐seminomatous germ cell tumours: outcomes and adjuvant chemotherapy

Ahmad Mousa iD, Lynn Anson-Cartwright, Eshetu G Atenafu, Michael A S Jewett iD, Philippe Bedard, Di Maria Jiang, Rachel Glicksman, Peter Chung, Padraig Warde, Martin O'Malley, Susan Prendeville, Robert J Hamilton

BJU International · 2024

DOI: 10.1111/bju.16448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2024. Verfasst von Ahmad Mousa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Lymph Node Excision. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dell'Elce Family Testis Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare the outcomes and treatment burden of primary retroperitoneal lymph node dissection (pRPLND) alone versus pRPLND + adjuvant chemotherapy (AC) in patients with pathological stage II (PSII) non‐seminomatous germ cell tumours (NSGCT). Patients and Methods Retrospective review of the Princess Margaret Cancer Center eTestes cancer database identified patients with PSII NSGCT after pRPLND between 1995 and 2020. The primary outcome was relapse‐free survival (RFS). Secondary outcomes included disease‐specific survival (DSS), burden of relapse treatment, and factors associated with relapse.

Results

A total of 109 PSII patients were included in the study. There were 96 patients treated with pRPLND alone and 13 treated with pRPLND + AC. The median follow‐up was 61 months. The 5‐year RFS was 72% for the pRPLND‐only group vs 92% for the pRPLND + AC group (hazard ratio [HR] 4.372, 95% confidence interval [CI] 0.59–32.36; P = 0.11). Within the pRPLND‐only group the 5‐year RFS differed by pN stage (pN1 = 94% vs pN2/N3 = 67%, P = 0.03). Despite a higher relapse rate within the pRPLND‐only group, the DSS was similar at 5 years (98% pRPLND only vs 100% pRPLND + AC, P = 0.48). Only 24 (25%) of the patients in the pRPLND‐only group required any subsequent chemotherapy. Despite achieving similar survival, the cumulative post‐RPLND treatment burden was less for the pRPLND‐only group than the pRPLND+AC group overall (average 1.23 vs 2.46 cycles of chemotherapy per patient in group).

Conclusion

The majority of patients with PSII NSGCT treated with pRPLND alone do not experience a recurrence or require chemotherapy. Despite a lower relapse risk when AC is given, no difference in survival was seen but higher chemotherapy burden was entertained. AC may constitute overtreatment for most patients with PSII NSGCT treated with pRPLND.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Germ Cell and EmbryonalTesticular NeoplasmsLymph Node ExcisionHumansMaleRetrospective StudiesAdultChemotherapy, AdjuvantRetroperitoneal SpaceTreatment OutcomeLymphatic MetastasisYoung AdultNeoplasm Staging

Stichwörter der Autor:innen

adjuvant chemotherapynon‐seminomaprimary retroperitoneal lymph node dissectionsurveillancetesticular cancer

Autor:innen und Institutionen

  • Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
  • Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • Biostatistics Core, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Ahmad Mousa, Michael A S Jewett

Förderung

  • Dell'Elce Family Testis Cancer Research Fund

Zitieren

APA

Mousa, A., Anson-Cartwright, L., Atenafu, E. G., Jewett, M. A. S., Bedard, P., Jiang, D. M., Glicksman, R., Chung, P., Warde, P., O'Malley, M., Prendeville, S., & Hamilton, R. J. (2024). Primary retroperitoneal lymph node dissection for metastatic non‐seminomatous germ cell tumours: outcomes and adjuvant chemotherapy. BJU International. https://doi.org/10.1111/bju.16448

Vancouver

Mousa A, Anson-Cartwright L, Atenafu EG, Jewett MAS, Bedard P, Jiang DM, et al. Primary retroperitoneal lymph node dissection for metastatic non‐seminomatous germ cell tumours: outcomes and adjuvant chemotherapy. BJU International. 2024. doi:10.1111/bju.16448

BibTeX
@article{Mousa2024,
  author = {Mousa, Ahmad and Anson-Cartwright, Lynn and Atenafu, Eshetu G and Jewett, Michael A S and Bedard, Philippe and Jiang, Di Maria and Glicksman, Rachel and Chung, Peter and Warde, Padraig and O'Malley, Martin and Prendeville, Susan and Hamilton, Robert J},
  title = {Primary retroperitoneal lymph node dissection for metastatic non‐seminomatous germ cell tumours: outcomes and adjuvant chemotherapy},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16448}
}
Kostenlos starten →